IDBS and Alchemi Partner to Automate Biopharma Regulatory Filings with AI Agents

IDBS and Alchemi have announced a partnership to connect Alchemi’s AI agents with the IDBS Polar platform, according to a press release. The collaboration aims to accelerate the preparation of regulatory filings in the biopharma industry while maintaining compliance with data integrity standards.

The integration links Alchemi’s purpose-built AI agents to data managed within the Polar system, allowing Chemistry, Manufacturing, and Controls (CMC) teams to generate technical and clinical reports more efficiently. Each document draft is routed through human review and recorded in a 21 CFR Part 11-compliant audit trail, ensuring traceability and validation.

In deployments across biopharma organizations, teams using Alchemi’s agents have produced regulatory documents up to 70 percent faster. The Polar platform captures structured and contextualized data throughout the drug development lifecycle, providing a governed foundation for AI systems operating in regulated environments.

Pietro Forgione, General Manager at IDBS, stated that the partnership supports the goal of accelerating regulatory milestones using compliant AI agents. Anuj Chadha, Co-Founder of Alchemi, said the integration enables submission-ready drafts to be produced in minutes while keeping the compliance trail intact.